1. Market Research
  2. > Proteinuria - Pipeline Review, H2 2013

Proteinuria - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 63 pages

Proteinuria - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Proteinuria - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Proteinuria. Proteinuria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Proteinuria.
- A review of the Proteinuria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Proteinuria pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Proteinuria.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Proteinuria pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Proteinuria - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Proteinuria Overview 7
Therapeutics Development 8
Pipeline Products for Proteinuria - Overview 8
Pipeline Products for Proteinuria - Comparative Analysis 9
Proteinuria - Therapeutics under Development by Companies 10
Proteinuria - Therapeutics under Investigation by Universities/Institutes 11
Proteinuria - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Proteinuria - Products under Development by Companies 16
Proteinuria - Products under Investigation by Universities/Institutes 17
Proteinuria - Companies Involved in Therapeutics Development 18
Questcor Pharmaceuticals, Inc. 18
GlaxoSmithKline plc 19
FibroGen, Inc. 20
Dimerix Bioscience Pty Ltd 21
InVasc Therapeutics, Inc. 22
Aurinia Pharmaceuticals Inc. 23
Proteinuria - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Assessment by Therapeutic Class 35
Drug Profiles 39
paricalcitol - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
FG-3019 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
losmapimod - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
INV-141 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
pioglitazone hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
corticotropin - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
INV-142 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Drug For Proteinuria - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
voclosporin - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Proteinuria - Recent Pipeline Updates 52
Proteinuria - Dormant Projects 59
Proteinuria - Product Development Milestones 60
Featured News and Press Releases 60
Nov 28, 2012: Anthera Pharma Announces Data From Phase IIb PEARL-SC Study Presented At 2012 Asian Lupus Summit 60
Dec 16, 2010: Evolva Begins Multiple Ascending Dose Study With EV-077 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63



List of Tables

Number of Products under Development for Proteinuria, H2 2013 8
Number of Products under Development for Proteinuria - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Stage Development, H2 2013 14
Comparative Analysis by Unknown Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Proteinuria - Pipeline by Questcor Pharmaceuticals, Inc., H2 2013 18
Proteinuria - Pipeline by GlaxoSmithKline plc, H2 2013 19
Proteinuria - Pipeline by FibroGen, Inc., H2 2013 20
Proteinuria - Pipeline by Dimerix Bioscience Pty Ltd, H2 2013 21
Proteinuria - Pipeline by InVasc Therapeutics, Inc., H2 2013 22
Proteinuria - Pipeline by Aurinia Pharmaceuticals Inc., H2 2013 23
Assessment by Monotherapy Products, H2 2013 24
Number of Products by Stage and Target, H2 2013 27
Number of Products by Stage and Mechanism of Action, H2 2013 30
Number of Products by Stage and Route of Administration, H2 2013 32
Number of Products by Stage and Molecule Type, H2 2013 34
Number of Products by Stage and Therapeutic Class, H2 2013 37
Proteinuria Therapeutics - Recent Pipeline Updates, H2 2013 52
Proteinuria - Dormant Projects, H2 2013 59



List of Figures

Number of Products under Development for Proteinuria, H2 2013 8
Number of Products under Development for Proteinuria - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Clinical Stage Development, H2 2013 13
Assessment by Monotherapy Products, H2 2013 24
Number of Products by Top 10 Target, H2 2013 25
Number of Products by Stage and Top 10 Target, H2 2013 26
Number of Products by Top 10 Mechanism of Action, H2 2013 28
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 29
Number of Products by Top 10 Route of Administration, H2 2013 31
Number of Products by Stage and Top 10 Route of Administration, H2 2013 32
Number of Products by Top 10 Molecule Type, H2 2013 33
Number of Products by Stage and Top 10 Molecule Type, H2 2013 34
Number of Products by Top 10 Therapeutic Class, H2 2013 35
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 36



Companies Mentioned

Questcor Pharmaceuticals, Inc.
GlaxoSmithKline plc
FibroGen, Inc.
Dimerix Bioscience Pty Ltd
InVasc Therapeutics, Inc.
Aurinia Pharmaceuticals Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.